Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 3/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.39 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.37 |
| ▸ | OGA | O60502 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24036427 | 0.92 | ROCK1 (0.46) | ROCK1LRRK2ACHEIRAK4PSMB8 | |
| SCHEMBL24035877 | 0.89 | ROCK1 (0.44) | ROCK1MKNK1MKNK2LRRK2ACHE | |
| SCHEMBL17162236 | 0.84 | ACHE (0.51) | ACHEPSMB8PSMB9OGA | |
| SCHEMBL12803551 | 0.83 | ROCK1 (0.48) | ROCK1NAMPTMKNK1MKNK2LRRK2 | |
| SCHEMBL23012191 | 0.82 | MKNK1 (0.49) | ROCK1NAMPTMKNK1MKNK2LRRK2 | |
| SCHEMBL24035880 | 0.81 | ACHE (0.60) | LRRK2ACHEPSMB8PSMB9OGA | |
| SCHEMBL3766078 | 0.80 | ACHE (0.58) | LRRK2ACHEPSMB8PSMB9 | |
| SCHEMBL24035776 | 0.78 | MPO (0.56) | ROCK1ACHEPSMB8PSMB9OGA | |
| SCHEMBL24035852 | 0.78 | DYRK1A (0.48) | ACHEPSMB8PSMB9OGA | |
| SCHEMBL22411770 | 0.78 | GSK3B (0.47) | ROCK1ACHEPSMB8PSMB9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230002403-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2021231474-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002403-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | ROCK1 1855/4885NAMPT 2265/4885MKNK1 778/4885 |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | ROCK1 1855/4885NAMPT 2265/4885MKNK1 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.